MD Anderson Cancer Center
1515 Holcombe Boulevard
309 articles about MD Anderson Cancer Center
Top research stories, including gene regulation and longevity, a head-to-head comparison of COVID-19 vaccines, a newly discovered type of brain cell and more.
Resilience and MD Anderson Launch Joint Venture to Accelerate Development and Manufacturing of Innovative Cell Therapies for Cancer
National Resilience, Inc. and The University of Texas MD Anderson Cancer Center announced the launch of a joint venture, the Cell Therapy Manufacturing Center, to accelerate the development and manufacturing of innovative cell therapies for patients with cancer.
OncoResponse is developing an innovative cancer therapy based upon antibodies produced by patients to components in the tumor microenvironment that regulate the immune response.
Typical metabolic syndrome treatment includes a healthy diet, exercise, and possibly metformin, but soon, there may be a new treatment. For that and more research news, continue reading.
James P. Allison will helm an innovation hub at The University of Texas MD Anderson Cancer Center that is focused on developing new immunotherapy breakthroughs in oncology.
Alpha Tau Announces New Research Collaboration to Study the Potential of Alpha DaRT to Enhance Immune Stimulation in the Treatment of Breast Cancer
Alpha Tau Medical Ltd. announced today that it has signed a sponsored research agreement with investigators at The University of Texas MD Anderson Cancer Center ("MD Anderson") to evaluate potential immune stimulation by combining Alpha DaRT™ with DNA-repair inhibitors and immune checkpoint inhibitors for the treatment of breast tumors.
Vaccine development is experiencing a resurgence in the wake of the COVID-19 pandemic, with companies developing a variety of approaches.
BridgeBio Pharma had inked a non-exclusive clinical partnership with Amgen to study a combination of its BBP-398 with Amgen’s Lumakras in advanced solid tumors with the KRAS G12C mutation.
Now, researchers are on the threshold of great changes that have the potential to transform non-curable diseases into those that can be cured.
At Harbinger, Hahn will oversee the development of the Bio-AI diagnostics platform dubbed HarbingerHx, in hopes of detecting cancer in a patient before it is visible or symptomatic.
“I hope to thread the needle between pricing responsibly and achieving profitability," Jarrett said.
An Inhaled Therapeutic Developed At Texas A&M Has Been Shown To Be Effective Against Most Known Respiratory Infections, Including COVID-19
There’s a new drug in development that could prevent the next global pandemic. Researchers at Texas A&M University Health Science Center ( Texas A&M Health ) and University of Texas MD Anderson Cancer Center are testing PUL-042, an inhaled therapeutic that provides broad protection against a range of life-threatening respiratory infections.
MD Anderson and Schrödinger Announce Strategic Research Collaboration to Accelerate Development of WEE1 Program
The University of Texas MD Anderson Cancer Center and Schrödinger, Inc. today announced a two-year strategic research collaboration focused on accelerating and optimizing the development of Schrödinger’s WEE1 inhibitor program, an investigational therapeutic approach designed to target the WEE1 kinase.
Bellicum and MD Anderson Announce Additional License Agreement for Use of CaspaCIDe® Safety Switch
Bellicum Pharmaceuticals, Inc . and The University of Texas MD Anderson Cancer Center today announced a global option and license agreement covering certain intellectual property and technology rights regarding Bellicum’s CaspaCIDe®
Blueprint, MD Anderson Cancer Center Accelerate Research Partnership To Develop Cancer Therapies
7/28/2021The research will focus on accelerating the capacities of BLU-222, an investigational therapy that Blueprint designed to target cyclin-dependent kinase 2 (CDK2).
The companies will co-finance a clinical study to test the combination of SHP2 inhibitor BBP-398 and OPDIVO in treating patients with advanced solid tumors KRAS mutations.
Hummingbird Bioscience and MD Anderson Announce Strategic Research Collaboration To Advance Innovative Immunotherapies
Hummingbird Bioscience and The University of Texas MD Anderson Cancer Center announced the launch of a multi-year strategic research collaboration to investigate and evaluate HMBD-002, Hummingbird's VISTA antagonist antibody.
Nucleix Establishes Collaborative Research and License Agreement with MD Anderson to Develop Methylation Assays to Assess Lung Cancer Patients
Nucleix , a liquid biopsy company revolutionizing cancer treatment by detecting the disease earlier, has entered into a collaborative research and license agreement with The University of Texas MD Anderson Cancer Center
KAHR Receives Investment from Cancer Focus Fund to Support Phase 1/2 Study of KAHR's Lead Anti-CD47 Candidate in Blood Cancers
KAHR and Cancer Focus Fund, LP, a unique venture capital fund established in collaboration with The University of Texas MD Anderson Cancer Center to provide funding and clinical expertise to advance promising cancer therapies, announced that Cancer Focus Fund is investing $5 million to finance a clinical trial of KAHR's lead anti-CD47 candidate, DSP107, in blood cancers.
MD Anderson and Refuge Biotechnologies Collaborate to Advance Next-Generation Cell Therapies for Treatment of Solid Tumors
Collaboration supports co-development of RB-340, a HER-2 targeted CAR T- cell therapy with context-dependent and inducible down-regulation of PD-1, through Phase 2 MD Anderson to apply Refuge’s synthetic biology platform to TIL programs